<form id="lwufo"><acronym id="lwufo"></acronym></form>
          Log in
          E-mail
          Password
          Remember
          Forgot password ?
          Become a member for free
          Sign up
          Sign up
          New member
          Sign up for FREE
          New customer
          Discover our services
          Settings
          Settings
          Dynamic quotes 
          OFFON

          MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

          GILEAD SCIENCES, INC.

          (GILD)
            Report
          SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
          News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

          Part of Gilead's coronavirus drug donation allocated to Japan

          share with twitter share with LinkedIn share with facebook
          05/14/2020 | 04:21pm EDT
          FILE PHOTO: An ampule of drugmaker Gilead's remdesivir, which has won emergency approval as a treatment for COVID-19 in Japan

          By Rocky Swift

          Japan has begun treating severely ill COVID-19 patients with Gilead Sciences Inc coronavirus drug remdesivir, days after granting emergency approval to the medication the company is supplying as part of its pledged donation.

          Japan's approval a week ago of remdesivir as a treatment for COVID-19 followed the U.S. Food and Drug Administration's emergency authorization of the antiviral drug on May 1.

          At that time, Foster City, California-based Gilead reiterated plans to donate 1.5 million doses of remdesivir - enough to treat at least 140,000 patients - "to help address the urgent medical needs posed by this pandemic around the world."

          The U.S. Department of Health and Human Services on Saturday said Gilead had committed to supply U.S. hospitals with about 607,000 vials of remdesivir, about 40% of the total 1.5 million-vial donation. After doctors had questioned the transparency of the allocation process, the federal agency said state health departments would distribute the intravenous drug.

          Gilead has not responded to requests for information about further global allocation plans. Company spokeswoman Seiko Noma confirmed in an email late Wednesday that an undisclosed portion of remdesivir vials have been donated to the Japanese government.

          "There are far more patients that may benefit from remdesivir than there are doses to go around." Dr. Michael Ison, professor of infectious diseases at Northwestern University Feinberg School of Medicine, said in a Journal of the American Medical Association editorial on Thursday.

          The Infectious Diseases Society of America on Thursday asked to meet with Dr. Deborah Birx, the White House Coronavirus Task Force coordinator, "to address ongoing questions regarding access to remdesivir and to inform planning for use of the drug." The medical group said uncertainty over those issues was interfering with patient care.

          Japan Ministry official Yasuyuki Sahara said in an e-mail on Thursday that the U.S. firm's treatment has been distributed to hospitals in Japan since May 11 and is being used for patients in intensive care or on ventilators.

          Sahara said the amount of remdesivir delivered by the drugmaker was not public information, and global supplies were "quite limited".

          Japan has had about 16,000 infections and 687 deaths from the coronavirus outbreak, much lower than many industrialised nations. The number of serious cases requiring ventilation was 259, according to the latest figures from the health ministry.

          The United States has nearly 1.4 million coronavirus infections and almost 84,000 deaths.

          With no other approved treatments for COVID-19, interest in remdesivir is growing around the world.

          Gilead on Tuesday said it had signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of remdesivir in more than 120 mostly low-income countries in Southeast Asia, Africa and other parts of the world.

          Gilead said the drug has improved outcomes for people suffering from the respiratory disease and has provided data suggesting it works better when given in the early stages of infection.

          Preliminary results from a trial led by the U.S. Institutes of Health showed remdesivir cut hospital stays by 31% compared with a placebo treatment, although it did not significantly improve survival.

          Remdesivir, which previously failed as a treatment for Ebola, is designed to stop some viruses making copies of themselves inside infected cells.

          (Additional reporting by Deena Beasely; Editing by Kenneth Maxwell and David Gregorio)

          Stocks mentioned in the article
          ChangeLast1st jan.
          ACCESS CO., LTD. -14.04% 814 End-of-day quote.-14.76%
          AMP LIMITED -1.72% 1.71 End-of-day quote.-10.70%
          AT HOME GROUP INC. 4.47% 8.64 Delayed Quote.57.09%
          DOW JONES AFRICA TITANS 50 INDEX 0.68% 473.34 Delayed Quote.-12.49%
          GILEAD SCIENCES, INC. -2.54% 73.64 Delayed Quote.13.33%
          JUST GROUP PLC -4.88% 45.66 Delayed Quote.-42.20%
          NORTHWESTERN CORPORATION 0.05% 54.79 Delayed Quote.-23.55%
          S&P AFRICA 40 INDEX 0.22% 158.04 Delayed Quote.-8.72%
          THE GLOBAL LTD. -2.27% 215 End-of-day quote.-54.35%
          THE NEW HOME COMPANY INC. -2.52% 4.25 Delayed Quote.-8.80%
          WILL GROUP, INC. -0.31% 644 End-of-day quote.-48.56%
          WORLD CO., LTD. -1.33% 1409 End-of-day quote.-47.64%
          share with twitter share with LinkedIn share with facebook
          Latest news on GILEAD SCIENCES, INC.
          07/24GILEAD SCIENCES : U.S. FDA Approves Kite's Tecartus™, the First and Only C..
          BU
          07/24GILEAD SCIENCES : Galapagos Say Arthritis Drug Gets Recommendation to Start Mark..
          DJ
          07/24GILEAD SCIENCES : EMA to review results from study testing common steroid drug a..
          RE
          07/24India sees record 49,000 new coronavirus cases, drug shortages in places
          RE
          07/22Pfizer, BioNTech Get $1.95 Billion Covid-19 Vaccine Order From U.S. Governmen..
          DJ
          07/21NICHI IKO PHARMACEUTICAL : Japan approves dexamethasone as coronavirus treatment
          RE
          07/21GILEAD SCIENCES : Buying Initial 49.9% Stake in Tizona Therapeutics for $300 Mil..
          DJ
          07/21GILEAD SCIENCES : Secures Exclusive Option to Acquire Tizona Therapeutics for $3..
          BU
          07/20CIPLA : Indian police arrest 14 for black market remdesivir as COVID-19 cases ju..
          RE
          07/17GILEAD SCIENCES : Infectious disease specialists ask U.S. govt to ensure remdesi..
          RE
          More news
          Financials (USD)
          Sales 2020 23 366 M - -
          Net income 2020 4 130 M - -
          Net cash 2020 1 219 M - -
          P/E ratio 2020 23,3x
          Yield 2020 3,71%
          Capitalization 92 372 M 92 372 M -
          EV / Sales 2019
          EV / Sales 2020 3,90x
          Nbr of Employees 11 800
          Free-Float 99,4%
          Chart GILEAD SCIENCES, INC.
          Duration : Period :
          Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
          Full-screen chart
          Technical analysis trends GILEAD SCIENCES, INC.
          Short TermMid-TermLong Term
          TrendsBearishNeutralBullish
          Income Statement Evolution
          Consensus
          Sell
          Buy
          Mean consensus OUTPERFORM
          Number of Analysts 31
          Average target price 81,28 $
          Last Close Price 73,64 $
          Spread / Highest target 31,7%
          Spread / Average Target 10,4%
          Spread / Lowest Target -15,8%
          EPS Revisions
          Managers
          NameTitle
          Daniel P. O'Day Chairman & Chief Executive Officer
          Andrew D. Dickinson Chief Financial Officer
          William A. Lee Executive Vice President-Research
          Merdad V. Parsey Chief Medical Officer
          George Pratt Shultz Director-Emeritus
          Sector and Competitors
          1st jan.Capitalization (M$)
          GILEAD SCIENCES, INC.13.33%92 372
          VERTEX PHARMACEUTICALS27.19%72 206
          REGENERON PHARMACEUTICALS62.18%61 840
          WUXI APPTEC CO., LTD.62.69%35 081
          GENMAB A/S50.79%22 826
          BEIGENE, LTD.35.40%20 085
          官方真人棋牌游戏平台